RT Journal Article T1 Low-dose sublingual fentanyl improves quality of life in patients with breakthrough cancer pain in palliative care. A1 Rodríguez, Albert Tuca A1 Viejo, Miguel Núñez A1 Maradey, Pablo A1 Canal-Sotelo, Jaume A1 Mancilla, Plácido Guardia A1 Rivero, Sonia Gutiérrez A1 Casillas, Inmaculada Raja A1 Abián, María Herrera A1 Bermudo, Cristina López K1 breakthrough cancer pain K1 pain management K1 palliative care K1 quality of life K1 transmucosal fentanyl AB Aim: This subanalysis of the CAVIDIOPAL study evaluated the impact of individualized management of breakthrough cancer pain (BTcP) with fentanyl on the quality of life (QoL) of advanced cancer patients in Spanish palliative care units. Patients & methods: This was a prospective, observational, multicenter study. The European Organization for Research and Treatment of Cancer's QLQ-C30 questionnaire was used at baseline (V0) and visit 28 (V28). Results: Ninety-five patients were mainly treated with 67-133 μg fentanyl, showing a notable reduction in intensity (visual analog scale: 8.0 [V0] to 4.6 [V28]), frequency and duration of BTcP episodes shortly after the first 1-2 weeks of treatment, with significantly improved QoL (global health status: 31.1 [V0] to 53.1 [V28]). Conclusion: Low-dose sublingual fentanyl effectively reduced BTcP in advanced cancer patients in palliative care units, significantly improving QoL. Clinical trial registration: NCT02840500 (ClinicalTrials.gov). YR 2022 FD 2022-02-09 LK http://hdl.handle.net/10668/20494 UL http://hdl.handle.net/10668/20494 LA en DS RISalud RD Apr 11, 2025